The past 14 days of consensus target-price revisions, as of July 13, 2026, reveal a notable tug-of-war between bullish healthcare sentiment and a concentrated wave of downward pressure hitting the energy and consumer staples sectors. While analysts are actively adjusting their outlooks, the sheer volume of bearish revisions suggests a cautious recalibration in specific, high-exposure industries.
Data shows that firms like B of A Securities have been particularly active, elevating targets across a range of healthcare stalwarts. Conversely, energy names and PepsiCo are facing a series of downward revisions from multiple houses, indicating a shift in consensus expectations that investors should weigh against the broader sector performance tracked on our latest moves page.
Firm-level moves
Healthcare has seen a clear pattern of upward revisions. B of A Securities adjusted Eli Lilly (LLY) from $1251 to $1334, while also lifting AbbVie (ABBV) from $234 to $276. Johnson & Johnson (JNJ) saw a modest bump from $254 to $263. Interestingly, Pfizer (PFE) bucked this trend within the same sector, with B of A lowering its target from $27 to $26.
Energy remains under the microscope, characterized by a wave of skepticism regarding Range Resources (RRC). RRC received three separate downward revisions on July 10, with targets falling from $49 to $44 (UBS), $46 to $43 (Truist), and $53 to $52 (Stephens & Co.). APA Corp also saw a cut from Truist, moving from $39 to $38. Similarly, PepsiCo (PEP) faced a barrage of four downgrades in a single day, with firms including Barclays, Jefferies, TD Cowen, and Morgan Stanley collectively pulling their targets down, with the most significant shift coming from Morgan Stanley at $180 to $160.
| Ticker | Firm | Dir | Prior→Current |
|---|---|---|---|
| ABBV | B of A | Up | $234→$276 |
| MSFT | Argus | Down | $620→$510 |
| RRC | UBS | Down | $49→$44 |
| PEP | Morgan Stanley | Down | $180→$160 |
Context
The most striking outlier in this data set is the revision for Microsoft (MSFT). Argus Research slashed its target from $620 to $510, a significant deviation from the prevailing sentiment for the tech giant. This move stands out sharply against the more incremental adjustments seen elsewhere in the industrials or financials sectors, such as the uptick in BlackRock (BLK) to $1145.
It is helpful to observe how geography and sector concentration dictate these moves. The cluster of downgrades for RRC and PEP suggests that institutional analysts are responding to common industry-wide headwinds rather than isolated company performance issues. By contrast, the healthcare upgrades appear to be individual firm-specific calls, reflecting a more idiosyncratic approach to valuation in the current climate. Watching these trends helps clarify whether a move represents a sector-wide signal or a singular, house-specific revision.